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Introduction
Despite cocaine abuse is a significant public health problem, an effective pharmacotherapeutic treatment is still lacking (Castells et al., 2010) . Identification of candidate biomarkers could assist in the development of effective pharmacological agents.
There is now considerable evidence that neurotrophins such as brain-derived neurotrophic factor (BDNF) and its intracellular signaling pathways are involved in psychostimulant abuse and dependence (see Corominas et al., 2007 for a review) . A single infusion of cocaine increases BDNF expression in the nucleus accumbens (NAc) (Filip et al., 2006) and prefrontal cortex (PFC) (Le Foll et al., 2005) . Cocaine selfadministration increases BDNF expression in the rat PFC, thereby modifying the reinforcing effects of cocaine (Sadri-Vakili et al., 2010) . In rodents treated repeatedly with cocaine, brain BDNF expression increases progressively after withdrawal (Grimm et al., 2003; Pu et al., 2006) .These studies also suggest that the progressive increase in BDNF expression in different brain areas after withdrawal is involved in incubation of cocaine craving (Grimm et al., 2003) and depressive behavioral symptoms (Filip et al., 2006) . Additionally, overexpression of BDNF in the mesolimbic system enhances locomotor sensitization and the rewarding effects of cocaine (Bahi et al., 2008) . Finally, heterozygous BDNF knockout mice (BDNF+/-) are less sensitive to the psychomotor stimulant and the rewarding effects of cocaine (Hall et al., 2003) .
Since BDNF crosses the blood-brain barrier in both directions (Pan et al., 1998) and can be measured in serum and plasma (Fujimura et al., 2002) , serum BDNF levels may reflect brain BDNF levels (Klein et al., 2011) . The first study assessing BDNF in cocaine addicts found no difference in BDNF serum levels in 15 cocaine addicts and a group of healthy controls (Angelucci et al., 2007) . However, a recent cross-sectional study of 22 cocaine-dependent individuals reported a significant correlation between serum BDNF and number of abstinence days (Hilburn et al., 2011) and recently, BDNF was reported to be increased after 3 weeks of withdrawal (D'Sa et al., 2011) .
In abstinent cocaine-dependent patients, an intense desire for the drug (craving) and symptoms of physical and mental distress are strong predictors of relapse (Garavan et al., 2000) . However, no controlled studies have linked these symptoms with blood BDNF levels. In the present study, we explored whether serum BDNF levels are a biomarker of cocaine craving and withdrawal.
Experimental procedures

Subjects
Patients met the diagnostic of cocaine addiction, according to the DSM-IV (American Psychiatric Association, 2000) criteria and were drawn from a cohort involved in an independent clinical study (ClinicalTrials.gov Identifier: NCT00495092).
Exclusion criteria included: 1) Lifetime history of substance use disorder except nicotine; 2) lifetime history of psychotic, bipolar, or substance abuse disorders; 3) current history of mood, psychotic or anxiety disorder; 4) organic illness; 5) being currently under psychotropic medication at least one month before joining the protocol; 6) seropositive for HIV; 7) psychotic symptoms during abstinence from or consumption of cocaine; 8) patients on chronic drug therapy with corticosteroids, thyroid hormones, allergy and/or analgesics. Sixty-two cocaine-dependent patients were assessed for eligibility; of these, 23 met the diagnostic criteria for inclusion (Figure 1) . A genderand age-matched sample of 46 healthy controls was also included. All participants were Caucasian and unrelated to one another.
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Blood sample collection AND BDNF measurements
Blood samples were collected twice, the first, immediately after arriving at the impatient facility and the second one, after twelve detoxification days. All patients had consumed cocaine the day before admission. 8 ml of blood was collected in anticoagulant-free tubes, kept at 4ºC for two hours, centrifuged at 3500 × g for 10 min at 4ºC and serum stored at -80ºC until performance of the BDNF assay. All samples were collected at fasting state and between 10 and 12 h to avoid circadian variations.
Levels of human BDNF in serum samples were measured using Aushon SearchLight Multiplex Array (Aushon BioSystems, Billerica, MA) a sandwich enzymelinked immunosorbent system. Each sample was analyzed twice and the mean of the two BDNF measurements was used. All mean intra-assay coefficients of variation were less than 20%.
Statistical analyses
Chi squared (for demographic categorical variables) and U Mann Whitney tests (for BDNF serum levels) were used to analyze differences between patients and controls and Wilcoxon signed-rank test for longitudinal changes in treated patients. Boxplots were additionally used to describe quartile (Q1), median (Q2) and upper quartile (Q3) of BDNF serum levels in both samples (pre and post in the case of patients), as they didn't follow a normal distribution. Spearman's Rho was used to correlate BDNF with age, consumption variables and baseline clinical (abstinence, craving, depression, anxiety)
measures. Kruskall wally's test was used to analyze the differences between the three treatment groups. A stepwise linear regression was used to assess the best clinical baseline correlates in BDNF serum change among the clinical sample. Statistical hypotheses were two-tailed and the risk alpha assumed was 5% in all analyses. All analyses were carried out using PASW Statistics software package, version 18.
Results
Demographic characteristics and evaluation of clinical symptoms
The Table 3 presents the BDNF serum levels in controls, patients at baseline, and patients after 12 days of abstinence. BDNF levels were significantly lower in patients at baseline than in controls (z = -3.488; p < .0001). BDNF levels increased significantly in patients across 12 days of abstinence (z = -2.173; p = .030). Analyses of normality showed that in patients, skewness and kurtosis was near 0 both at intake and after 12 days of abstinence, whereas in controls skewness was 1.6 and kurtosis was 3.6, indicating a leptokurtic distribution. Figure 2 depicts Q1, Q2, and Q3 in controls, patients at intake, and patients after 12 days of abstinence. Figure 2 . Boxplot of BDNF serum levels. Serum brain-derived neurotrophic factor (BDNF) levels (ng/mL median) obtained from the control group (left; n=46), for the patients group at baseline (middle, patients pre, n=23) and after 12 days of early detoxification treatment (right, patients post, n=23). Statistical sig-nificant differences in BDNF serum levels were found (1) at baseline between controls and patients and (2) across 12 days of abstinence between baseline and post-early detoxification
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Correlations between BDNF levels and demographic factors and clinical symptoms
No correlation was found between BDNF levels and age among patients or controls. We were unable to assess correlations of BDNF levels with gender due to the small number of females in our sample. No differences were found between pharmacological treatment groups hence, we pooled the patient data for these analyses.
Of the clinical symptom measures, only craving VAS correlated significantly with baseline BDNF serum levels in patients. By contrast, post-detoxification BDNF levels correlated with craving VAS, CCQ loss of control, CSSA, BDI, and STAI trait.
The increase in BDNF levels from intake to post-detoxification correlated with craving VAS, CCQ loss of control, CSSA, and BDI (Table 4 ).
Página 12 de 21 most predictive of the change in BDNF levels in patients. The loss of control subscale of the CCQ was the only variable that remained in the model (β = .840; p < .005). The model was statistically significant (F = 16.81; p < .005) and the percentage of explained variance was 71% (R-squared = .706). Figure 3 shows a scatterplot comparing the change in BDNF levels to baseline loss of control CCQ scores, along with a regression line. 
Discussion
Due to the small sample size, the results of this study have to be considered as preliminary and future studies involving larger samples will be needed. In interpreting these results, it is also necessary to take into account that about half of the patients received oral caffeine during detoxification. Although BDNF is increased after caffeine administration to zebrafish whose embryos were previously treated with caffeine (Capiotti et al., 2011) or in caffeine-treated sleep-deprived rats (Alhaider et al., 2011), we did not find differences in BDNF serum levels between caffeine-and placebotreated abstinent cocaine addicts. This may be due to the predominance of cocaine withdrawal over the stimulant effects of caffeine, an antagonist of adenosine receptors, during the first two abstinence weeks. Hence, for further comparisons in this study, data from all treatment groups were pooled and analyzed together.
Our results show a decrease of serum BDNF levels in cocaine dependent individuals, suggesting neurotoxic effects induced by chronic cocaine consumption. We also observed a significant increase in BDNF serum levels in cocaine-dependent individuals during early abstinence with the magnitude of the increase being predictive of craving. The low levels of serum BDNF in cocaine-dependent patients compared to healthy controls was somewhat unexpected, as preclinical studies in rodents report an increase in BDNF protein expression in different brain regions following acute cocaine (Le Foll et al., 2005; Liu et al., 2006) . There are several possible explanations for this apparent inconsistency. First, chronic cocaine administration may have different effects than acute cocaine administration. Preclinical studies report no change in BDNF protein levels in the first days after withdrawal from chronic cocaine (Grimm et al., 2003; Pu et al., 2006) and clinical studies with human addicts show no differences in BDNF serum levels between addicts and healthy controls (Angelucci et al., 2007) .
Second, the effects of chronic cocaine consumption and withdrawal in humans differ in several respects from those seen in animal models. For example, stress vulnerability, anxiety, and depression are associated with cocaine abuse in humans (Herrero et al., 2008) and this may explain low BDNF levels reported in this study.
Indeed, in our sample of cocaine-dependent patients, baseline anxiety and depression were moderately high (Table 2) . Chronic stress prevents cocaine-induced BDNF upregulation in the PFC (Fumagalli et al., 2009) , and low serum BDNF has been consistently reported as a biomarker for depressive-like states (Schmidt and Duman, 2010) . Additionally, cocaine dependence is associated with dysregulation of the hypothalamic-pituitary-adrenal axis and increased cortisol (Fox et al., 2009 ) which in turn is associated with a decrease in BDNF expression (Fanous et al., 2010) . According to the role of BDNF in the regulation of neuronal connectivity, synaptic plasticity and survival of dopamine neurons (Thoenen, 1995; Fritsch et al., 2011) , low BDNF serum levels in cocaine-dependent patients may induce neuronal toxicity and thereby compromise synaptic plasticity in mesolimbic regions.
Our findings show a significant increase in serum BDNF levels over the first 12 days of abstinence (table 3) that appears to be independent of the caffeine treatment.
Serum BDNF increased in patients being in an inpatient facility with locked doors and small and controlled environmental space that may have prevented a greater increase of BDNF during withdrawal treatment. This reported increase is consistent with preclinical models in which BDNF increases progressively in the brain (Pu et al., 2006; SadriVakili et al., 2010) up to 90 days of abstinence (Grimm et al., 2003) . Our results are also in accordance with D'sa et al. (2011) who reported higher BDNF serum levels in a sample of cocaine-dependents after three abstinence weeks as compared to healthy controls. These changes in serum BDNF during early cocaine abstinence may be due to compensatory mechanisms to the neurotoxic effects of chronic cocaine (Sadri-Vakili et al., 2010) .
One of the main findings of our study is the significant positive relationship between the increase in serum BDNF levels over early abstinence and cocaine craving.
This finding is consistent with previous research. In rodent cocaine self-administration models, there is a positive relationship between the increase of BDNF in brain regions and cue-induced drug-seeking after cocaine withdrawal (Grimm et al., 2003) . In addicts, serum BDNF correlates with the time of cocaine relapse (D'sa et al., 2011) . We also found a positive relationship between symptoms of abstinence, anxiety, and depression and increasing serum BDNF levels during early abstinence. In neuroimaging, cueelicited cocaine craving in addicts is associated with activation of mesocorticolimbic areas (Garavan et al., 2000) . Given the role of BDNF in the regulation of neuronal connectivity and synaptic plasticity (Thoenen, 1995; Fritsch et al., 2011) , our data suggest functional changes in mesolimbic neuronal networks during cocaine abstinence which may underlie abnormal brain activation and emotional and behavioral correlates of cocaine craving. Together these data suggest that serum BDNF levels may be a biomarker of neuroplastic changes that lead to loss of control over consumption and to relapse.
In conclusion, chronic cocaine use is associated with decreased baseline serum BDNF levels and serum BDNF levels rise during early abstinence. The progressive increase in serum BDNF levels during early withdrawal may reflect rising BDNF levels in brain regions involved in cocaine craving. Furthermore, these changes in BDNF expression may affect synaptic plasticity in regions of the mesolimbic system that underlie craving and contribute to addiction. Taken together, these findings suggest that serum BDNF levels may be a biomarker in cocaine addiction. Pharmacological agents that interact with BDNF may have clinical utility in the treatment of cocaine addiction.
